Overview
- The peer-reviewed study found that levels of the thymus-produced peptide fall with age and that restoring it in aged mice reduced harmful myeloid cytokine release and slowed tumor growth.
- Mechanistic experiments showed the peptide suppresses inflammatory signaling by inhibiting NF-κB in myeloid cells and raises interferon-gamma production by tumor-infiltrating CD4+ and CD8+ T cells.
- In aged mouse breast-cancer models the treatment improved survival and made tumors more responsive to anti-PD-L1 immunotherapy.
- Analyses of human blood and breast-tumor datasets revealed age-linked increases in pro-inflammatory myeloid signatures, linking the animal findings to patterns seen in older patients but not proving causation.
- Authors and funders say the result points to a translational path for treating inflammaging and improving cancer care for older adults, yet safety, dosing, and efficacy must be tested in clinical trials and across more disease models.